Cytodyn Inc
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colo… Read more
Cytodyn Inc (CYDY) - Total Assets
Latest total assets as of November 2025: $8.94 Million USD
Based on the latest financial reports, Cytodyn Inc (CYDY) holds total assets worth $8.94 Million USD as of November 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cytodyn Inc - Total Assets Trend (2010–2025)
This chart illustrates how Cytodyn Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cytodyn Inc - Asset Composition Analysis
Current Asset Composition (May 2025)
Cytodyn Inc's total assets of $8.94 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 66.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Cytodyn Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytodyn Inc's current assets represent 99.1% of total assets in 2025, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 66.0% of total assets in 2025, down from 93.6% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Cytodyn Inc Competitors by Total Assets
Key competitors of Cytodyn Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cytodyn Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cytodyn Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Cytodyn Inc generates $ 20.75 in net profit.
Cytodyn Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.10 | 0.35 | 1.13 |
| Quick Ratio | 0.10 | 0.35 | 0.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-76.27 Million | $ -45.99 Million | $ 15.06 Million |
Cytodyn Inc - Advanced Valuation Insights
This section examines the relationship between Cytodyn Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1066.03 |
| Latest Market Cap to Assets Ratio | 14.78 |
| Asset Growth Rate (YoY) | 62.1% |
| Total Assets | $18.05 Million |
| Market Capitalization | $266.75 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cytodyn Inc's assets at a significant premium ( 14.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Cytodyn Inc's assets grew by 62.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cytodyn Inc (2010–2025)
The table below shows the annual total assets of Cytodyn Inc from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-05-31 | $18.05 Million | +62.06% |
| 2024-05-31 | $11.14 Million | -1.38% |
| 2023-05-31 | $11.29 Million | -61.31% |
| 2022-05-31 | $29.18 Million | -77.90% |
| 2021-05-31 | $132.08 Million | +161.47% |
| 2020-05-31 | $50.51 Million | +141.99% |
| 2019-05-31 | $20.87 Million | +326.09% |
| 2018-05-31 | $4.90 Million | -39.18% |
| 2017-05-31 | $8.06 Million | -41.57% |
| 2016-05-31 | $13.79 Million | +194.62% |
| 2015-05-31 | $4.68 Million | -44.47% |
| 2014-05-31 | $8.43 Million | +102.69% |
| 2013-05-31 | $4.16 Million | +288.21% |
| 2012-05-31 | $1.07 Million | -46.32% |
| 2011-05-31 | $2.00 Million | +166.71% |
| 2010-05-31 | $748.00K | -- |